The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe Medication Practices today voiced strong support for the Mitigating Emergency Drug Shortages Act (S.2723), which includes provisions recommended by a recent drug shortages summit convened by the organizations. Introduced by Sens. Susan Collins, R-Maine, and Tina Smith, D-Minn., the legislation would require manufacturers to disclose the root causes and expected duration of shortages, and develop contingency plans to ensure an ongoing supply. It also would extend reporting requirements to include contract manufacturers and active pharmaceutical ingredients; develop recommendations to incentivize manufacturers to enter the market for drugs in shortage; and examine the national security risk of shortages.
 
“Over the past decade, America’s hospitals and health systems have experienced far too frequent shortages of widely used drugs that are absolutely crucial to patient care and public health,” said AHA Executive Vice President Tom Nickels. “The AHA thanks Senators Susan Collins and Tina Smith for their bipartisan commitment to tackling the issue of drug shortages by introducing today’s legislation. We look forward to working with Congress to advance the MEDS Act, which will help prevent, mitigate and resolve drug shortages and secure the supply of these life-saving products for patients and the hospitals and health systems that proudly care for them.”
 
A report released today by the Food and Drug Administration identifies a lack of manufacturer incentives to produce less profitable drugs and focus on continuous quality improvement, and logistical and regulatory challenges that make it difficult for the market to recover from a disruption as root causes for the nation’s drug shortages. Requested by members of Congress, the report recommends actions to create a shared understanding of the impact of drug shortages and the contracting practices that may contribute to them, and developing a system to rate and reward high-quality drug manufacturing facilities. It also recommends promoting sustainable private-sector contracts to ensure a reliable supply of medically important drugs, among other actions.
 

Related News Articles

Headline
The House July 3 voted 218-214 to pass the final version of the One Big Beautiful Bill Act (H.R. 1), which enacts many of President Trump’s legislative…
Headline
The American Society for Health Care Engineering July 1 announced 87 health care facilities as winners of the 2025 Energy to Care Sustainability Champions…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The Senate narrowly passed the One Big Beautiful Bill Act (H.R. 1) on July 1 by a 50-50 tally, with Vice President J.D. Vance casting the tie-breaking vote.…
Headline
The AHA June 29 sent a letter to senators urging them to amend the budget reconciliation bill before its final passage in the Senate. The Senate version of the…
Headline
The AHA June 16 released a fact sheet with analysis on the impact to rural patients and hospitals from proposed Medicaid cuts by Congress. The analysis found…